ERBB2 and cancer: Thus, the emodin compound azide methyl anthraquinone derivative (AMAD) blocks the phosphorylation of Her2/neu, suppressing the growth, transformation, and metastasis of cancer cells, which has similar effects to standard cytotoxic therapeutic agents and thus may represent a potential therapeutic strategy for blocking signaling pathways [69,70].